Table 1.

Examples of chemical inhibitors of lipid enzymes that could reduce fatty acid availability. Shown are selected inhibitors for enzymes mentioned in text.

Enzyme	Inhibitor	Comments	Selected References
ACC	Soraphen-A		(Beckers et al., 2007)
	TOFA (5-(tetradecyloxy)- 2-furoic acid)		(Pizer et al., 2000), (Guo et al., 2009a)
	A-769662		(Göransson et al., 2007)
	Metformin	Indirect, activates AMPK	(Pollak, 2012)
	AICAR	Indirect, activates AMPK	(Jose et al., 2011)(Swinnen et al., 2005)
ACLY	SB-204990		(Hatzivassiliou et al., 2005), (Ros et al., 2012)
	LY294002	Indirect, PI3K inhibitor	(Migita et al., 2008)
ACS	Triacscin C		(Mashima et al., 2005)
	Thiazolidinediones (TZDs)	ACSL4 specific, also activates PPARγ, FDA approved	(Kim et al, 2001)
AGPAT	CT-32501	AGPAT2 specific	(Takeuchi and Reue, 2009)
CKα	TCD-717	Currently in phase I trials	http://clinicaltrials.gov/show/NCT01215864
	MN58B		(Glunde et al., 2011)
CIC	Benzene-tricarboxylate analog (BTA)		(Catalina-Rodriguez et al., 2012)
CPT1	Etomoxir		(Samudio et al., 2010) (Pike et al., 2011)
	Ranolazine	FDA approved	(Samudio et al., 2010)
FASN	Cerulenin and its derivative C75		(Lupu and Menendez, 2006) (Ros et al., 2012)
	Orlistat	FDA approved	(Lupu and Menendez, 2006)
	Flavonoids	Naturally occurring	(Lupu and Menendez, 2006)
	Epigallocatechin-3-gallate (EGCG)	Found in green tea	(Lupu and Menendez, 2006)
MAGL	JZL184		(Nomura et al., 2010)
SCD	BZ36		(Fritz et al., 2010)
	A939572		(Roongta et al., 2011)
SREBP	Fatostatin	Inhibits processing of SREBP-1 and -2	(Williams et al, 2013)
	FGH10019	Inhibits processing of SREBP-1 and -2	(Williams et al, 2013) (Kamisuki et al, 2011)